Article Synopsis
- Physiological functions shift throughout the day due to natural rhythms like sleep/wake cycles and environmental changes, with the circadian system helping the body adapt for optimal health.
- Disruptions to this circadian rhythm, primarily from nighttime artificial light exposure, increase risks for cardiovascular and metabolic issues.
- Regular exercise, especially in the evening, shows potential benefits in managing these risks and may help realign the circadian system for better health outcomes.
Video Abstracts
Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Physiological function fluctuates across 24 h due to ongoing daily patterns of behaviors and environmental changes, including the sleep/wake, rest/activity, light/dark, and daily temperature cycles. The internal circadian system prepares the body for these anticipated behavioral and environmental changes, helping to orchestrate optimal cardiovascular and metabolic responses to these daily changes. In addition, circadian disruption, caused principally by exposure to artificial light at night (e.g., as occurs with night-shift work), increases the risk for both cardiovascular and metabolic morbidity and mortality. Regular exercise is a countermeasure against cardiovascular and metabolic risk, and recent findings suggest that the cardiovascular benefits on blood pressure and autonomic control are greater with evening exercise compared to morning exercise. Moreover, exercise can also reset the timing of the circadian system, which raises the possibility that appropriate timing of exercise could be used to counteract circadian disruption. This article introduces the overall functional relevance of the human circadian system and presents the evidence surrounding the concepts that the time of day that exercise is performed can modulate the cardiovascular and metabolic benefits. Further work is needed to establish exercise as a tool to appropriately reset the circadian system following circadian misalignment to preserve cardiovascular and metabolic health. © 2022 American Physiological Society. Compr Physiol 12:3621-3639, 2022.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214902 | PMC |
| http://dx.doi.org/10.1002/cphy.c210036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Observational and Experimental Evidence on the Interaction Between Fine Particulate Matter and Shared Genetic Variants Across Atherosclerotic Cardiovascular Disease Subtypes.
Circ Genom Precis Med
September 2025
Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China (J.Z., S.R., L.C., M.C., F.T., B.A., Y.Y., H.L.).
Background: Previous studies have suggested that the associations between ambient air pollution and atherosclerotic cardiovascular diseases (ASCVD) differ by genotype. A genome-wide approach provides a more comprehensive understanding of this relationship on a genomic scale.
Methods: Using data from ≈300 000 UK Biobank participants, we conducted a genome-wide interaction analysis on 10 745 802 variants.
Large-Scale Proteomics-Based Risk Score for the Prediction of Incident Cardio-Kidney-Metabolic Disease Risk.
Circ Genom Precis Med
September 2025
Division of Cardiology, Emory University School of Medicine, Atlanta, GA. (A.K.Y., A.C.R., L.S.S., A.A.Q., Y.V.S.).
Background: Cardio-kidney-metabolic (CKM) disease represents a significant public health challenge. While proteomics-based risk scores (ProtRS) enhance cardiovascular risk prediction, their utility in improving risk prediction for a composite CKM outcome beyond traditional risk factors remains unknown.
Methods: We analyzed 23 815 UK Biobank participants without baseline CKM disease, defined by -Tenth Revision codes as cardiovascular disease (coronary artery disease, heart failure, stroke, peripheral arterial disease, atrial fibrillation/flutter), kidney disease (chronic kidney disease or end-stage renal disease), or metabolic disease (type 2 diabetes or obesity).
Relationships of Circulating Plasma Metabolites With the QT Interval in a Large Population Cohort.
Circ Genom Precis Med
September 2025
Clinical Pharmacology and Precision Medicine, William Harvey Research Institute, London, United Kingdom (W.J.Y., M.M.S., J.R., S.v.D., H.R.W., A.T., P.B.M.).
Background: There is a higher prevalence of heart rate corrected QT (QTc) prolongation in patients with diabetes and metabolic syndrome. QT interval genome-wide association studies have identified candidate genes for cardiac energy metabolism, and experimental studies suggest that polyunsaturated fatty acids have direct effects on ion channel function. Despite this, there has been limited study of metabolite concentration relationships with QT intervals.
View Article and Find Full Text PDF[Biomarkers for an early detection of patients at risk of renal or cardiovascular disease].
Rev Med Liege
September 2025
Service de Chimie clinique, CHU Liège, Belgique.
Chronic kidney disease (CKD), heart failure (HF) and atherosclerotic cardiovascular disease (ASCVD) are pathologies that may remain silent for a long time and thus are largely underdiagnosed in clinical practice. The use of biomarkers may help detect people already suffering from these diseases at an early stage or at increased risk to develop them in a near future. The aim of this article is to discuss the place of the assays of albuminuria, natriuretic peptide (BNP/proBNP) and high-sensitivity troponin as well as lipoprotein(a) to help in the diagnosis and prognosis assessment of individuals at risk of presenting or developing a CKD, HF or ASCVD.
View Article and Find Full Text PDFVariation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information-Based Mapping Exercises Across the 42 Integrated Care Boards of England.
Clin Obes
September 2025
Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Obesity medications are recommended in England with legislation necessitating their availability. However, given the number of people who meet clinically approved eligibility criteria, funding these medications and associated support services may limit efficacy at a population health level. This study aimed to assess the commissioning and availability of services and obesity medications across England.
View Article and Find Full Text PDF